Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
News|Articles|February 27, 2017
Thermo to Provide Cryo-TEM Services for NovAliX’s Laboratory
Author(s)Pharmaceutical Technology Editors
Thermo Fisher Scientific will provide cryo-TEM for small-molecule and biologic drug discovery.
Advertisement
On Feb. 27, 2017, Thermo Fisher Scientific announced that the company will provide high-resolution cryo-transmission electron microscopy (cryo-TEM) for NovAliX’s new contract research laboratory. The facility will provide services for small-molecule and biologic drug discovery.
NovAliX’s new laboratory will use the cryo-TEM to provide two-dimensional and three-dimensional characterization of small-molecule and biological samples. In a press announcement, Thermo said that NovAliX has completed its first program with a Japanese pharmaceutical customer. The company has multiple projects planned with additional customers.
“Cryo-TEM has great potential in drug discovery applications; it is highly complementary to traditional methods, such as x-ray crystallography, and nuclear magnetic resonance,” said Denis Zeyer, CEO, NovAliX in a statement. “For small-molecules research, cryo-TEM provides structural information about multi-protein complexes or membrane proteins. For biologics, cryo-TEM can deliver critical information about antibody selection, epitope mapping, and formulation. This information helps the drug discovery process to become more consistent and reproducible, which may ultimately result in better therapeutic candidates.”
NovAliX’s new laboratory also includes x-ray diffraction, nuclear magnetic resonance, micro-array surface plasmon resonance, and other technologies. The addition of cryo-TEM enables NovAliX to resolve features in biological molecules, sufficient to reveal tertiary and quaternary protein structure and, in some cases, to identify individual amino acid side chains. It can look at molecules and molecular complexes of any size, without crystallization. Equally important, cryo-TEM samples, which are frozen in vitreous (non-crystalline) ice, can be examined in a near-native, fully-hydrated state. Cryo-TEM has proven to be complementary to nuclear magnetic resonance spectroscopy and x-ray diffraction as researchers have used computational techniques to fit their atomic-scale information into cryo-TEM 3D models.
Source: Thermo Fisher Scientific
Advertisement
Related to this article
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Advertisement
Advertisement